GlassScriptPhysician profile
Saifullah Siddiqui
NPI 1801187968
$10,152.61
in general payments reported to CMS, 2019-2025
41 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2021: $397 · 2022: $1,403 · 2023: $724 · 2024: $4,167 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,413 · Travel and Lodging: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,412.87 |
| Travel and Lodging | $1,374.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,851.17 | 2024 | Ruby Coil, Indigo System |
| Edwards Lifesciences Corporation | $1,614.74 | 2021-2024 | Sapien 3 Ultra Resilia, Pascal |
| Medtronic Vascular, INC. | $1,565.85 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $382.12 | 2024-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $379.26 | 2022-2025 | |
| Abbott Laboratories | $356.32 | 2021-2024 | Mitraclip, Diamondback Peripheral |
| Abiomed | $315.95 | 2023-2025 | Impella |
| Pfizer INC. | $282.17 | 2022-2025 | |
| Novo Nordisk INC | $281.27 | 2024-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $250.30 | 2021-2025 | Wainua, Farxiga |
| Boston Scientific Corporation | $218.50 | 2024-2025 | Watchman Flx, S-Icd System Magnet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.49 | 2021-2025 | Lifevest |
| Teleflex LLC | $204.21 | 2023-2025 | Manta, Turnpike |
| Merck Sharp & Dohme LLC | $201.66 | 2023-2025 | Verquvo, Winrevair |
| Amgen INC. | $198.89 | 2023-2025 | Repatha, Repatha |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $194.42 | 2023-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $193.44 | 2023-2025 | Onpattro, Amvuttra |
| W. L. Gore & Associates, INC. | $181.94 | 2023 | Gore Cardioform Septal Occluder |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.85 | 2023-2025 | Jardiance |
| Cvrx, INC. | $145.26 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $128.69 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $126.71 | 2024-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $79.89 | 2024-2025 | |
| Heartflow, INC. | $76.23 | 2025 | |
| Siemens Medical Solutions USA, INC. | $67.62 | 2021 | |
| Kestra Medical Technology Services, INC. | $56.37 | 2024-2025 | Assure Wcd |
| Livanova USA, INC. | $43.56 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $41.22 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $41.13 | 2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $40.92 | 2023-2024 | Inpefa |
| Chiesi USA, INC. | $33.09 | 2025 | Kengreal, Cleviprex |
| Bridgebio Pharma, INC. | $31.40 | 2025 | Attruby |
| Daiichi Sankyo INC. | $27.40 | 2024 | Injectafer |
| Inspire Medical Systems, INC. | $25.82 | 2024 | Inspire |
| Inari Medical, INC. | $24.99 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $23.12 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cardiovascular Systems INC. | $20.28 | 2021-2022 | |
| Mannkind Corporation | $19.50 | 2025 | |
| Lilly USA, LLC | $18.79 | 2025 | Zepbound |
| Idorsia Pharmaceuticals US INC | $17.12 | 2025 | Tryvio |
| Medtronic, INC. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saifullah Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.